Li, J., Cheng, Y., Bai, C., Xu, J., Shen, L., Li, J., Zhou, Z., Li, Z., Chi, Y., Yu, X., Li, E., Xu, N., Liu, T., Lou, W., Bai, Y., Yuan, X., Wang, X., Yuan, Y., Chen, J., Guan, S., Fan, S., & Su, W. (2023). corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1–9]. European journal of cancer, 178, 247–248. http://access.bl.uk/ark:/81055/vdc_100172522370.0x000039